AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 20 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Patients with vesical carcinoma in situ or high-grade superficial bladder tumors receive no clinical benefit from continued administration of intravesical bacillus Calmette-Guerin (BCG) instillations after the initial treatment.
Researchers in Spain had proposed that patients who were successfully treated with BCG the first time might be able to maintain their disease-free status with periodic follow-up treatments.
Six months after treatment with six instillations of Connaught strain BCG, 131 patients who were disease-free were randomly assigned to receive either continued treatment with six instillations every six months for two years or no treatment, reported J. Palou and associates.
Of the 65 patients on maintenance therapy, 22 (33.85%) completed the planned two-year treatment. At a mean follow-up of 79 months, neither group had an advantage in terms of recurrence or progression, the authors said.
A total of 16 patients (26.2%) in the control groups and 10 (15.1%) in the maintenance group had superficial relapse at a mean of 24 and 20 months, respectively ("Control group and maintenance treatment with ...
Source: HighBeam Research, Maintenance Therapy With Bacillus Calmette-Guerin Not...